RedHill Biopharma Ltd.

Entera Bio developed a delivery platform for replacing injections with pills; the Company has two drugs in clinical phases; market potential for their platform is significant; Entera Bio recently entered into a $270 million license agreement with Amgen; price target is set at $17.6

Read More »

Revolutionary technology enables cardiologists to make better decisions and results in 30% assumed revenue growth by the end of 2019; Itamar Medical has a $6.8B addressable market with limited competition; we start our coverage with a price target of 1.51 NIS.

Read More »

Allot Allows Telecom Providers to Leverage Their Networks for Increased Revenues; We view Allot`s Mobile Network Security operations as a growth engine for the company’s revenues in the coming years; we initiate coverage on Allot at a share price target of $12.0

 

Read More »

Vonetize. After delay, launch of operations in Russia expected by the end of 2018; the company needs additional sources of funding; acquisition by Desilu Studios is still awaiting completion; target price has been reduced to NIS 1.00.

Read More »

Kadimastem has raised NIS 15M which will fund clinical and pre-clinical development for cellular therapy; target price unchanged.

Read More »

SAFE-T. NASDAQ IPO – $7.3M raised strengthens equity structure; significant growth in revenues and backlog offset by a substantially increased burn rate due to operational and technological expansion; valuation retained, however due to additional shares, target price decreased to NIS 3.85.

Read More »

RedHill announces top-line results from Phase III study of RHB-104 in Crohn’s Disease; cash balance improved with $25M (gross) raised at a discount; Top-line results for TALICIA® (RHB-105) – H. pylori infection expected by the end of 2018; target price reduced to NIS 2.23

Read More »

Enlight Renewable Energy. Increase in revenue from electricity sales in H1-2018 due to full commercial operation in Ireland and in Croatia; Housing Cabinet approval for the Bereshit Project received; Acquisition of rights to a wind energy project in Spain; All other projects are progressing as scheduled; In light of the company meeting our expectations stock target price remains unchanged.

Read More »

Energix. Favorable regulatory changes in Poland support the continued growth of the company’s operations; Expectation of regulatory progress in the company’s flagship project – the Aran project in the Golan Heights; all projects in development are progressing according to schedule; target price remains at NIS 4.61.

Read More »

DNA. Entera is now trading under NASDAQ:ENTX; Entera has completed Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism; BeamMed posted impressive revenue growth, with a strategic focus on the US; target price increased by 50% to NIS 1.19.

Read More »